NCT04516278Phase 3Completed

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Study sponsor: Outlook Therapeutics, Inc. · OTLK

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-02-10Actual
Enrollment · participants197Actual
Source updated2026-07-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency and Incidence of Treatment-emergent Adverse Events. After: Measure: Number of Participants With Adverse Events.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency and incidence of treatment-emergent adverse events. After: Measure: Frequency and Incidence of Treatment-emergent Adverse Events.

Actual enrollment increased by 2 participants

Before: 195 participants (actual). After: 197 participants (actual).

Check registry source